Compound ID | Pharmacophoric 3D features predicted by our models | |||||||
---|---|---|---|---|---|---|---|---|
Quinoline | N1 | 4-amino | 4-anilino benzene | R7 | R′3 | R′4 | R′5 | |
AQ (Lead) | H; AR | HBA | HBD | AR | H | PI; H | HBA; HBD | - |
659 | H; AR | HBA | HBD | AR | H; HBA | PI | HBA;HBD | PI |
649 | H; AR | HBA | HBD | AR | H; HBA | PI | HBD | PI |
289 | H; AR | HBA | HBD | AR | H | PI | HBD | PI |
299 | H; AR | HBA | HBD | AR | H | PI | HBA;HBD | PI |
1029 | H; AR | HBA | HBD | AR | H | PI | HBA;HBD | PI |
1009 | H; AR | HBA | HBD | AR | H | PI | HBD | PI |
1019 | H; AR | HBA | HBD | AR | H | PI | HBA;HBD | PI |
403 | H; AR | HBA | HBD | AR | H; HBA | PI | HBD | PI |
454 | H; AR | HBA | HBD | AR | H; HBA | PI; H; H | HBA;HBD | PI; H; H |
413 | H; AR | HBA | HBD | AR | H; HBA | PI | HBA;HBD | PI |
464 | H; AR | HBA | HBD | AR | H; HBA | PI; H; H | HBA;HBD | PI; H; H |
444 | H; AR | HBA | HBD | AR | H; HBA | PI; H; H | HBD | PI; H; H |
340 | H; AR | HBA | HBD | AR | H | AR; H; H | HBA;HBD | AR; H; H |
597 | H; AR | HBA | HBD | AR | H; HBA | PI; H; H | HBA; H; AR | PI; H; H |
577 | H; AR | HBA | HBD | AR | H; HBA | PI; H; H | HBA;HBD | PI; H; H |
43 | H; AR | HBA | HBD | AR | H | PI | HBD | PI |